Sign In
Buy APLT
$0.0959
+0 (+0%)
At Close: Apr 28, 2026
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) con
NEW YORK CITY, NY / ACCESSWIRE / December 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" o
Applied Therapeutics, Inc. (APLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
08:07am, Sunday, 08'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) con
Bronstein, Gewirtz & Grossman, LLC Is Investigating Applied Therapeutics, Inc. (APLT) And Encourages Investors to Connect
07:00am, Sunday, 08'th Dec 2024
NEW YORK CITY, NY / ACCESSWIRE / December 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" o
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) con
Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors
02:08pm, Friday, 06'th Dec 2024
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics”) common stock (NASDAQ: A
Investors who lost money on Applied Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - APLT
07:25am, Friday, 06'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) con
NEW YORK CITY, NY / ACCESSWIRE / December 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" o
Applied Therapeutics, Inc. Being Investigated on Behalf of Applied Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
04:30pm, Thursday, 05'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) con
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
04:00pm, Thursday, 05'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:APLT). Such
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) con
NEW YORK CITY, NY / ACCESSWIRE / December 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" o
APLT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Applied Therapeutics, Inc. Shareholders Who Lost Money
07:25am, Wednesday, 04'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) con
NEW YORK CITY, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" o
Applied Therapeutics says it received FDA's warning letter for genetic disease drug study
06:34pm, Monday, 02'nd Dec 2024
Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after the U.S. health regulator declined to approve the treatment last week.
